http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yong-Kyu Chung,Shin Hwang,Gi-Won Song,Young-Joo Lee,Ki-Hun Kim,Chul-Soo Ahn,Deok-Bog Moon,Tae-Yong Ha,Dong-Hwan Jung,Gil-Chun Park,Baek-Yeol Ryoo,Sung-Gyu Lee 한국간담췌외과학회 2018 Annals of hepato-biliary-pancreatic surgery Vol.22 No.4
Backgrounds/Aims: Hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) and liver transplantation (LT) remains a great concern. We assessed the antitumor effects of metformin in patients treated with sorafenib for HCC recurrence after HR or LT. Methods: The two clinical retrospective studies involved metformin therapy of 304 HR patients and 74 LT recipients who were treated with sorafenib. Results: In the study involving patients who had undergone HR, death occurred in 245 of the 304 patients (80.6%) during a median follow-up of 10.2 months after sorafenib administration. The metformin HR group (group 1; n=40) showed no prognostic difference in progression-free and overall survival rates compared with the all-HR control group (group 3; n=241) and propensity score-matched HR control group (group 4; n=80). In the clinical study of recipients exposed to LT, death occurred in 62 of the 74 patients (83.8%) during a median follow-up of 13.6 months (range: 3-76 months) after sorafenib administration. The metformin LT group (group 5; n=14) showed no prognostic difference in progression-free and overall survival rates compared with the all-LT control group (group 7; n=43) and propensity score-matched LT control group (group 8; n=28). Conclusions: Our clinical studies demonstrated absence of synergistic antitumor effects of metformin. Further high-volume studies are necessary to assess the role of metformin in patients treated with sorafenib for advanced HCC.
a-Si TFT Integrated Gate Driver Using Multi-thread Driving
Jang, Yong-Ho,Yoon, Soo-Young,Park, Kwon-Shik,Kim, Hae-Yeol,Kim, Binn,Chun, Min-Doo,Cho, Hyung-Nyuck,Choi, Seung-Chan,Moon, Tae-Woong,Ryoo, Chang-Il,Cho, Nam-Wook,Jo, Sung-Hak,Kim, Chang-Dong,Chung, I The Korean Infomation Display Society 2006 Journal of information display Vol.7 No.3
A novel a-Si TFT integrated gate driver circuit using multi-thread driving has been developed. The circuit consists of two independent shift registers alternating between the two modes, "wake" and "sleep". The degradation of the circuit is retarded because the bias stress is removed during the sleep mode. It has been successfully integrated in 14.1-in. XGA LCD Panel, showing enhanced stability.
( Won-mook Choi ),( Jonggi Choi ),( Danbi Lee ),( Ju Hyun Shim ),( Young-suk Lim ),( Han Chu Lee ),( Young-hwa Chung ),( Young-sang Lee ),( Sook Ryun Park ),( Min-hee Ryu ),( Baek-yeol Ryoo ),( So Jun 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Regorafenib and nivolumab are drugs approved for second-line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared. Methods: This study retrospectively evaluated 373 patients with HCC who were treated with regorafenib (n=223) or nivolumab (n=150) after sorafenib failure between July 2017 and February 2019. Results: Progression-free survival (PFS; hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.69-1.06; P=0.150), time to progression (TTP; HR, 0.95; 95% CI, 0.77-1.19; P=0.680), and overall survival (OS; HR, 0.83; 95% CI, 0.64-1.07; P=0.154) did not differ significantly between groups of patients treated with regorafenib and nivolumab, findings consistently observed by multivariable-adjusted, propensity score-matched, and inverse probability treatment weighting (IPTW) analyses. However, the objective response rate was significantly higher in the nivolumab than in the regorafenib group (13.3% vs, 4.0%; P=0.002). When the effectiveness of regorafenib and nivolumab was compared in non-progressors to treatment, defined as patients who achieved complete response, partial response, or stable disease after first response evaluation, PFS (HR, 0.50; 95% CI, 0.33-0.75; P=0.001), TTP (HR, 0.48; 95% CI, 0.31-0.73; P<0.001), and OS (HR, 0.51; 95% CI, 0.31-0.87; P=0.013) were significantly longer in the 59 non-progressors to nivolumab than in the 104 non-progressors to regorafenib, findings also observed by multivariable-adjusted and IPTW analyses. Conclusions: Survival outcomes in patients treated with regorafenib and nivolumab after sorafenib failure did not differ significantly. However, nivolumab may be more effective than regorafenib in non-progressors.
Kang, Hye Jin,Ryu, Min-Hee,Kim, Kyoung-Mee,Park, Young Soo,Choi, Jene,Ryoo, Baek-Yeol,Kim, Woo Ho,Im, Seock-Ah,Bang, Yung-Jue,Park, Se Hoon,Lee, Jae-Hyuk,Chung, Ik Joo,Bae, Han-Ik,Kim, Jong Gwang,Lee, Informa Healthcare 2012 Acta Oncologica Vol.51 No.4
<P><I>Purpose.</I> To assess the efficacy of imatinib for different tumor genotypes in Korean patients with advanced gastrointestinal stromal tumors (GIST). <I>Material and methods</I>. Clinical data were collected from 370 consecutive patients with locally advanced unresectable, metastatic, or recurrent GIST treated with imatinib 400 mg/day between August 2001 and December 2007 at 20 Korean institutions. Tumor genotypes were determined for 290 patients by direct DNA sequencing of <I>KIT</I> exons 9, 11, 13, and 17, and <I>PDGFRA</I> exons 12, 14, and 18. <I>Results.</I> Of 290 patients assessed for genotype, 261 (90.0%) had mutations in <I>KIT</I>: 222 (76.6%) in exon 11, 35 (12.1%) in exon 9 and two each (0.7%) for exons 13 and 17. Four patients (1.4%) had mutations in the <I>PDGFRA</I> gene: one in exon 12, and three in exon 18. Twenty-five patients (8.6%) had no detectable mutations. The best responses of the 235 patients with measurable lesions were: 15 complete response (6.4%), 126 partial response (53.5%), 86 stable disease (36.6%), and eight progressive disease (3.4%). Patients with <I>KIT</I> exon 9 mutations, compared with patients with <I>KIT</I> exon 11 mutations, had a lower objective response rate (36.7% vs. 63.6%, p == 0.007) and a shorter progression-free survival (median 28.7 months vs. 49.4 months, p == 0.001). No statistical difference in overall survival was observed between these genotypes. <I>Conclusion.</I> This study confirms that imatinib efficacy is dependent on genotype in Korean GIST patients, consistent with results demonstrated by Western patients with GIST.</P>
A Case of Composite (Mixed) denocarcinoma-Small Cell Carcinoma of the Stomach
Kim, Nam Don,Park, Yeon Hee,Ki, Seung Seog,Park, Yong Jin,Kim, Heoyng Joon,Ryoo, Baek-Yeol,Kim, Heung Tae,Chung, Jin-Haeng,Yuh, Young Jin 인제대학교 백병원 2003 仁濟醫學 Vol.24 No.1
A composite (mixed) tumor is defined as a glandular-endocrine cell carcinomas characterized by an intricate admixture of both elements in the same lesion. The histogenesis of this tumor is not clear but is considered to be multidirectional differentiation from pluripotential stem cells. The clinical findings are local symptoms due to mass and systemic symptoms due to paraneoplastic syndrome. The prognosis is considered to be very poor because of a high incidence of vasculo-lymphatic invasion and markedly deep infiltration of small cell carcinoma (SCC) of this composite tumor. Treatment has not been established clearly yet, but treatment with regimens specific for SCC of the lung may be used because the biologic and clinical characteristics of gastric SCC are similar to those of SCC of the lung. We encountered a 70-year-old man with pain to the back and both elbows for 20 days on July 22, 2002. Esophagogastroduodenoscopic biopsy revealed a superficially well differentiated adenocarcinoma and a deeply located. poorly differentiated SCC in the same lesion of the stomach, along with multiple bony metastases. We treated the patient with a chemotherapeutic regimen (etoposide and carboplatin) and palliative radiotherapy. The patient complained of sustained abdominal pain and poor oral intake and he died about 5 months later.